Study name	Statistics for each study				Risk ratio and 95% CI				
	Risk ratio	Lower limit	Upper limit	p-Value					
Cooper 2021	3.573	0.793	16.088	0.097				+	
Farcy 2022	1.797	0.074	43.764	0.719		6-14			
Ganesh.b 2021	0.515	0.123	2.151	0.363		_			
Heller 2023	4.636	0.207	103.895	0.334		30 <u></u>	0	-	-
McCreary 2021	1.086	0.143	8.236	0.936		19:	-		
Monday 2022	3.561	0.372	34.054	0.270					<u>=</u>
Savoldi 2022	2.944	0.600	14.441	0.183			-		
Webb 2021	0.725	0.030	17.683	0.844				-	
	1.718	0.857	3.446	0.127	20	8	•		10
					0.01	0.1	1	10	100
					Ba	mlanivima	ab (Other mAl	bs

Figure 1 Forest plot analysis for the outcome of mortality rate of bamlanivimab versus mAbs in patients with COVID-19.




Figure 2 Forest plot analysis for the outcome of hospitalization rate of bamlanivimab versus mAbs in patients with COVID-19.




Figure 3 Forest plot analysis for the outcome of ED visit of bamlanivimab versus mAbs in patients with COVID-19.




Figure 4 Forest plot analysis for the outcome of ICU admission of bamlanivimab versus mAbs in patients with COVID-19.





Figure 5 Forest plot analysis for the outcome of adverse events of bamlanivimab versus mAbs in patients with COVID-19.



0

Log odds ratio

-4

-3

-2

-1

Figure 6 Funnel plot of included studies for mortality rate.

3

2




Figure 7 Funnel plot of included studies for hospitalization rate.

Table 1 Risk of bias of included studies (ROBINS-I)

				deviations			
Study	Confounding	Selection	Classification of interventions	from intended interventions	Missing Data	Measurement of outcomes	Reported Result
Alam	Moderate	Low	Low	Low	Low	Moderate	Low
Bariola	Low	Low	Low	Low	Low	Low	Low
Brock	Moderate	Moderate	Low	Low	Low	Moderate	Low
Cooper	Low	Low	Low	Low	Low	Low	Low
Corwin	Moderate	Low	Low	Low	Low	Moderate	Low
Destache	Low	Low	Low	Low	Low	Moderate	Low
Djuric	Moderate	Moderate	Low	Low	Moderate	Moderate	Low
Farcy	Moderate	Low	Low	Low	Low	Low	Low
Filippo	Moderate	Low	Low	Low	Low	Moderate	Low
Ganesh.a	Low	Low	Low	Low	Low	Low	Low
Ganesh.b	Low	Low	Low	Low	Low	Low	Low
Heller	Moderate	Low	Low	Low	Low	Moderate	Low
Iqbal	Moderate	Low	Low	Low	Low	Moderate	Low
Karr	Moderate	Low	Low	Low	Low	Low	Low
Kumar	Moderate	Low	Low	Low	Low	Low	Low
McCreary	Moderate	Moderate	Low	Low	Low	Moderate	Low
Monday	Moderate	Low	Low	Low	Low	Low	Low
Murillo	Moderate	Low	Low	Low	Low	Low	Low
Priest	Moderate	Low	Low	Low	Low	Low	Low
Quenzer	Moderate	Low	Low	Low	Moderate	Low	Low
Rubin	Moderate	Low	Low	Low	Moderate	Low	Low
Savoldi	Moderate	Low	Low	Low	Low	Low	Low
Sridhara	Low	Low	Low	Low	Moderate	Moderate	Low
Voelker	Moderate	Moderate	Low	Low	Low	Moderate	Low
Webb	Moderate	Low	Low	Low	Low	Moderate	Low

Note: Moderate= the study is sound for a non-randomized study with regard to this domain but cannot be considered comparable to a well-performed randomized trial; Low=the study is comparable to a well-performed randomized trial with regard to this domain.

Table 2 Risk of bias of included studies (RoB)

Study	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting
Chen	Low	Unclear	Unclear	Unclear	Low	Low
Chew	Low	Unclear	Low	Low	Low	Low
Cohen	Low	Unclear	Low	Low	Low	Low
Gottlieb	Low	Unclear	Low	Low	Low	Low
Lundgren	Low	Unclear	Low	Low	Low	Low